Orphazyme A/S (ORPH)
| Market Cap | 140.43M |
| Revenue (ttm) | 13.15M |
| Net Income (ttm) | n/a |
| Shares Out | 34.95M |
| EPS (ttm) | -4.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,578,067 |
| Open | 4.06 |
| Previous Close | 4.12 |
| Day's Range | 3.85 - 4.10 |
| 52-Week Range | 3.78 - 77.77 |
| Beta | 0.70 |
| Analysts | Strong Buy |
| Price Target | 21.15 (+435.5%) |
| Est. Earnings Date | n/a |
About ORPH
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, In...
Analyst Forecast
According to 3 analysts, the average rating for Orphazyme stock is "Strong Buy." The 12-month stock price forecast is 21.15, which is an increase of 435.50% from the latest price.
News
Bank Stocks: Why BAC, WFC and MS Investors Are Smiling Today
Bank stocks are on the move Thursday following the release of earnings reports from various companies and we've got the details. The post Bank Stocks: Why BAC, WFC and MS Investors Are Smiling Today app...
ORPH Stock Alert: What's Going on With Red-Hot Orphazyme Today?
Today, retail investors and traders appear willing to put some big money down on Orphazyme and ORPH stock as a potential short-squeeze play. The post ORPH Stock Alert: What's Going on With Red-Hot Orpha...
Orphazyme provides regulatory and financial updates
Orphazyme A/SCompany announcement No. 22/2021Company Registration No. 32266355
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourag...
LOS ANGELES, Sept. 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the C...
ORPH Final Deadline Today: Rosen, Leading Trial Attorneys, Encourages Orphazyme A/S Investors with Losses in Excess o...
New York, New York--(Newsfile Corp. - September 7, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/...
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encou...
Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S (...
Final Deadline for Investors with Losses Exceeding $500K to Actively Participate in the Orphazyme A/S (ORPH) Class Ac...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or "the Company") (NA...
ORPH Final Deadline Tomorrow: Rosen, Top Ranked Global Counsel, Encourages Orphazyme A/S Investors with Losses to Sec...
New York, New York--(Newsfile Corp. - September 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Orphazyme A/S of Class ...
NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH) and certain of its officers...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme ...
LOS ANGELES--(BUSINESS WIRE)---- $ORPH #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Orphazyme A/S (ORPH)
TUESDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and...
Los Angeles, California--(Newsfile Corp. - September 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S (...
TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S a...
Los Angeles, California--(Newsfile Corp. - September 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S (...
Orphazyme reports business highlights and financial results in Interim Report First Half 2021
Orphazyme A/SCompany announcement No. 21/2021CVR No.: 32266355
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Importa...
NEW YORK, Aug. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orp...
Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021
Orphazyme A/SInvestor news No. 08/2021Company Registration No. 32266355
CytRx Highlights Orphazyme's Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...
Dear ORPH Stock Fans, Here Is the Latest Trial News You Should Be Cheering
Today, ORPH stock is trading significantly higher after the company announced some positive clinical trial data for its lead drug candidate. The post Dear ORPH Stock Fans, Here Is the Latest Trial News ...
Investors React Positively To Data From Orphazyme's Neurodegenerative Disease Candidate
Orphazyme A/S (NASDAQ: ORPH) announced that results from a Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C (NPC) had been published in the peer-reviewed Journal of Inherited Metabolic Dise...
Orphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C in ...
Orphazyme A/SInvestor news No. 07/2021Company Registration No. 32266355
Rosen, A Leading Law Firm, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before...
New York, New York--(Newsfile Corp. - August 20, 2021) - WHY: New York, N.Y., August 20, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (N...
ORPH NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orphazyme A/S Investors with Losses in Excess of $100K ...
NEW YORK, Aug. 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orp...
Rosen, Top Ranked Investor Counsel, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important...
New York, New York--(Newsfile Corp. - August 14, 2021) - WHY:. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/o...
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit A...
BENSALEM, Pa., Aug. 13, 2021 /PRNewswire/ -- Law Offices of Howard G.
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerativ...
What's Next For Orphazyme Stock?
Orphazyme A S ADR (NASDAQ: ORPH) shares are higher Wednesday, as traders were able to push the stock up. There looks to be no company-specific news to cause the jump in share price.